Sangamo Biosciences (SGMO) Tops Q1 EPS by 6c

Go back to Sangamo Biosciences (SGMO) Tops Q1 EPS by 6c

BMO Capital Starts Sangamo BioSciences (SGMO) at Outperform

April 22, 2015 4:31 PM EDT

BMO Capital initiates coverage on Sangamo BioSciences (NASDAQ: SGMO) with a Outperform rating and a price target of $19.00.

Analyst Jim Birchenough commented, "Our favorable outlook is based on its novel and proprietary approach to gene editing, a deep pipeline of gene therapy opportunities with competitive advantage,... More